Rheumatology

Alvotech Locks In $65 Million for Biosimilar Development

October 27th 2020

By Tony Hagen

With a sizeable round of fresh capital, Alvotech hopes to bring monoclonal antibodies and fusion proteins through the development pipeline.

Safety, Efficacy, and Savings Result From Study of Nonmedical Switching

October 26th 2020

By Tony Hagen

Article

A study of mandatory switching for patients with rheumatologic conditions led to savings without effect on safety or efficacy.

Samsung Bioepis Presents Real-World Switching Data for Renflexis

October 26th 2020

By Tony Hagen

Article

A retrospective analysis of data from the US Veterans Affairs Healthcare System database provides positive switching data for infliximab products.

Europeans Devise Checklist for Promoting Biosimilar Use

October 24th 2020

By Deana Ferreri, PhD

Article

European investigators have derived a set of core principals for developing higher utilization of biosimilars.

Biocon Reports Biosimilars Revenue Growth

October 23rd 2020

By Tony Hagen

Article

Biocon had a busy quarter, which included the launch of a long-acting insulin glargine product (Semglee) in partnership with Mylan.

Biogen, Samsung Report Third-Quarter Biosimilar Results

October 21st 2020

By Tony Hagen

Article

Earnings fell overall for Biogen, although biosimilar revenues continued an upward climb.

NeuClone's Ustekinimab Candidate Shines in Phase 1 Trial

October 20th 2020

By Tony Hagen

Article

Demonstrated biosimilarity across clinical parameters puts this drug among NeuClone's leading product candidates.

CT-P10 and Reference Rituximab Evaluated in Primary Sjögren Syndrome

October 20th 2020

By Deana Ferreri, PhD

Article

Investigators note similar efficacy and safety profiles in real-life study of reference and biosimilar forms of rituximab.

Avalere: Step Therapy May Exacerbate Patient, Payer Costs

October 19th 2020

By Tony Hagen

Article

An Avalere analysis suggests costs are more moderate and lower under a no–step therapy scenario for patients with Crohn disease.

ICER: Infliximab Is Highest in Cost-Effectiveness for UC

October 19th 2020

By Skylar Jeremias

Article

Reviewers found that costs of reference infliximab and its biosimilars make it the most cost-effective therapy for ulcerative colitis (UC) among targeted immune modulators.